Analysis in progress
Initialising…
0%
complete
This report is still being assembled — sections appear as each stage finishes. It isn't final yet.
MLH3
Final classification
VUS
MLH3 c.20T>A · p.Val7Asp
MLH3

NM_001040108.2:c.20T>A (p.Val7Asp) is a missense variant in exon 2 of MLH3, a DNA mismatch repair gene associated with autosomal dominant Lynch syndrome and autosomal recessive polyposis predisposition.

Gene
MLH3
Transcript
NM_001040108.2
HGVS · transcript:coding
NM_001040108.2:c.20T>A
Consequence
N/A
GRCh38
chr14:75049636 A>T
GRCh37
chr14:75516339 A>T
Basis gene-specific framework lacked a usable explicit final combination framework, so generic ACMG/AMP 2015 final-combination rules were applied as fallback; applied criteria: PM2 supporting; combination = 1 supporting, which maps to VUS.
gene-specific framework lacked a usable explicit final combination framework, so generic ACMG/AMP 2015 final-combination rules were applied as fallback; applied criteria: PM2 supporting; combination = 1 supporting, which maps to VUS.
Classification rationale
PM2 VUS
MLH3 c.20T>A

NM_001040108.2:c.20T>A (p.Val7Asp) is a missense variant in exon 2 of MLH3, a DNA mismatch repair gene associated with autosomal dominant Lynch syndrome and autosomal recessive polyposis predisposition. This variant is absent from gnomAD v2.1 and v4.1 population databases, supporting PM2 at a supporting strength level.1 Multiple computational predictors do not support a deleterious effect: REVEL score is 0.384 (intermediate), BayesDel is −0.281 (benign-leaning), and SpliceAI predicts no splice impact (max delta 0.00). PP3 is not met.2 The variant has been reported once in ClinVar as Uncertain significance by a single clinical laboratory (Ambry Genetics; Variation ID 1785889); no pathogenic or benign consensus exists.3 No variant-specific functional studies, case-control data, cosegregation evidence, or de novo observations were identified for this variant in the available evidence sources. The PVS1 criterion is not applicable as this is a missense change (p.Val7Asp) that does not meet the ClinGen SVI PVS1 null-variant criteria (PMC6185798).4 The variant has been observed once in a somatic cancer context (COSMIC COSV53136280), which is not directly informative for germline pathogenicity classification.

PM2 VUS
Gene diagram · NM_001040108.2 · variants mapped to exon structure
MLH3 NM_001040108.2
Fetching transcript structure from UCSC…
Applied criteria · 1 applied · 20 assessed
Applied · 1
Strength Supporting Moderate Strong Very strong
PM2 supporting Pathogenic
NM_001040108.2:c.20T>A is absent from gnomAD v2.1 and v4.1 population databases, meeting the PM2 threshold for a variant with allele frequency below 0.1% in controls.
Absent from gnomAD v2.1 (exomes)absent from gnomAD v4.1 (exomes+genomes).
Assessed · not applied
Pathogenic
PS1 No established pathogenic variant with the same amino acid change (p.Val7Asp) at this residue has been identified in ClinVar or the literature.
PS2 No de novo occurrence of NM_001040108.2:c.20T>A has been reported in a patient with confirmed parental relationships.
PS3 No well-established functional studies demonstrate a deleterious effect of p.Val7Asp on MLH3 protein function.
PS4 No case-control or cohort data demonstrate enrichment of NM_001040108.2:c.20T>A in affected individuals compared to controls.
PM1 The variant lies at residue 7 in MLH3, which is not within a statistically significant cancer hotspot and does not fall within a well-characterized critical functional domain without benign variation.
PM6 No assumed de novo without paternity/maternity confirmation has been reported for NM_001040108.2:c.20T>A.
PP1 No cosegregation data with disease has been reported for this variant in affected families.
PP2 Insufficient gene-level constraint data (missense Z-score, benign missense rate) available to determine whether MLH3 has a low rate of benign missense variation that would qualify for PP2.
PP3 Multiple lines of computational evidence do not support a deleterious effect: REVEL score 0.384 (below typical pathogenic threshold), BayesDel score -0.281 (benign-leaning), and SpliceAI max delta 0.00 (no predicted splice impact).
PP4 No specific phenotype or family history data are available for the individual harboring NM_001040108.2:c.20T>A to assess phenotypic specificity for MLH3-associated disease.
PP5 No reputable source (e.g., expert panel, clinical laboratory consensus) reports NM_001040108.2:c.20T>A as pathogenic.
Benign
BA1 The variant is absent from gnomAD v2.1 and v4.1; allele frequency does not exceed the 1% threshold for BA1.
BS1 The variant is absent from gnomAD v2.1 and v4.1; allele frequency does not exceed the 0.3% threshold for BS1.
BS2 The variant has not been observed in a homozygous state in healthy adults, nor has it been observed at a frequency inconsistent with MLH3-associated disease penetrance.
BS3 No well-established functional studies demonstrate a neutral or non-deleterious effect of p.Val7Asp on MLH3 protein function.
BS4 No non-segregation data with disease in affected families is available for NM_001040108.2:c.20T>A.
BP2 No evidence that NM_001040108.2:c.20T>A has been observed in trans with a known pathogenic MLH3 variant in the context of a fully penetrant dominant disorder.
BP4 Computational evidence is mixed and does not consistently support a non-deleterious effect: BayesDel predicts benign (-0.281), but REVEL is intermediate (0.384) and SpliceAI is neutral (max delta 0.00).
BP5 No case has been identified where NM_001040108.2:c.20T>A was found in a patient with an alternate molecular basis for MLH3-associated disease.
BP6 No reputable source reports NM_001040108.2:c.20T>A as benign or likely benign.
N/A · 4 PVS1 · PM5 · BP1 · BP7
Research & evidence
Population frequency
gnomAD v4.1 screenshot
gnomAD v4.1
gnomAD v2.1 screenshot
gnomAD v2.1
v4.1
Absent from gnomAD v4.1.
v2.1
Absent from gnomAD v2.1.
🇨🇦 CA
This variant is absent from gnomAD-Canada.
Allele frequency by ancestry
three datasets · side by side
gnomAD v4.1
Absent · 0 / ?
0 hom
Not observed in any ancestry group.
gnomAD v2.1
Absent · 0 / ?
0 hom
Not observed in any ancestry group.
gnomAD Canada 🇨🇦
Absent · 0 / ?
0 hom
Not observed in any ancestry group.
ClinVar screenshot
ClinVar
This variant has been reported in ClinVar as Uncertain significance (1 clinical laboratory). (ClinVarID = 1785889)
SpliceAI screenshot
In silico
SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00). REVEL score = 0.384. BayesDel score = -0.280993.
Functional / OncoKB screenshot
Functional Unknown Oncogenic Effect
OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. MLH3, a DNA mismatch repair protein, is infrequently altered in cancer.
OncoKB ↗
COSMIC screenshot
COSMIC
Cancer hotspots screenshot
Cancer hotspots
Somatic evidence Not in COSMIC / hotspots
COSMIC
This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV53136280, n = 1 times).
Hotspots
This variant does not lie in a statistically significant hotspot.
Sources & reference links
7Sources
ClinVar
gnomAD v2.1
gnomAD v4.1
SpliceAI
OncoKB
COSMIC
Cancer hotspots